NCT01628432

Brief Summary

The study compares the effect of bilateral salpingectomy associated with conservative hysterectomy on ovarian function to the standard hysterectomy with conservation of both ovaries and tubes in terms of hormone assays, ovarian ultrasound evaluation, complications, quality of life.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
350

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 22, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

June 26, 2012

Completed
5 days until next milestone

Study Start

First participant enrolled

July 1, 2012

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

October 22, 2018

Status Verified

October 1, 2018

Enrollment Period

4.8 years

First QC Date

June 22, 2012

Last Update Submit

October 19, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • percentage of patients with more than 20% diminution of AMH logarithm at one year (12 months)

    one year

Secondary Outcomes (1)

  • AMH measurement at 3 days, 6 weeks, and 6, 12 months after hysterectomy endovaginal ultrasound evaluation of the ovarian volume and vascularisation quality of life (WHQ questionnaire) reintervention procedures complications

    day3, week 6, month 6 and month 12

Study Arms (2)

conservative hysterectomy I

EXPERIMENTAL

bilateral salpingectomy during hysterectomy with conservation of the ovaries

Procedure: conservative hysterectomy I

conservative hysterectomy II

ACTIVE COMPARATOR

standard conservative hysterectomy with conservation of both ovaries and tubes

Procedure: Conservative hysterectomy II

Interventions

conservative hysterectomy for benign disease

conservative hysterectomy I

bilateral salpingectomy during hysterectomy without conservation of the ovaries

conservative hysterectomy II

Eligibility Criteria

Age18 Years - 52 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • age ≥ 18 years and less than 52 years
  • indication of a conservative hysterectomy for benign disease
  • signed informed consent
  • non menopausal women (AMH \>0,21 ng/ml)

You may not qualify if:

  • pregnancy
  • desire of future pregnancy
  • menopausal status
  • patient unable to give informed consent
  • any physical or psychiatric condition that could impair with patient's ability to cooperate with post operative data collection
  • previous salpingo and /or oophorectomy (unilateral or bilateral)
  • genital cancer disease or atypical endometrial hyperplasia
  • hyperandrogenia
  • any ovarian mass that needs surgical exploration
  • any immunotherapy that could interfere with immunological tests

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

CHU

Angers, 49933, France

Location

CHU

Le Kremlin-Bicêtre, 94 275, France

Location

CHU

Lille, 59 037, France

Location

Hôpital Sud

Lyon, 69495, France

Location

CHU

Poitiers, 86000, France

Location

CHU

Rennes, 35203, France

Location

CHU

Tours, 37044, France

Location

MeSH Terms

Conditions

Genital Diseases, FemaleAdenomyosisEndometriosisMetrorrhagiaUterine Cervical DysplasiaUterine Prolapse

Condition Hierarchy (Ancestors)

Female Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital DiseasesUterine DiseasesUterine HemorrhageHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsPrecancerous ConditionsNeoplasmsUterine Cervical DiseasesPelvic Organ ProlapseProlapsePathological Conditions, Anatomical

Study Officials

  • Lobna OULDAMER, MD

    CHRU de TOURS

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 22, 2012

First Posted

June 26, 2012

Study Start

July 1, 2012

Primary Completion

May 1, 2017

Study Completion

June 1, 2018

Last Updated

October 22, 2018

Record last verified: 2018-10

Locations